Cargando…
Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent
Glaucoma has a significant impact on quality of life. Here, we aimed to evaluate the influence of a reduction in glaucoma medications on quality of life and patient satisfaction after phacoemulsification combined with the Xen gel stent. We carried out a cross-sectional survey of patients who underwe...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225126/ https://www.ncbi.nlm.nih.gov/pubmed/35743517 http://dx.doi.org/10.3390/jcm11123450 |
_version_ | 1784733542957187072 |
---|---|
author | Pahljina, Christian Sarny, Stephanie Hoeflechner, Lukas Falb, Thomas Schliessleder, Gernot Lindner, Marlene Ivastinovic, Domagoj Mansouri, Kaweh Lindner, Ewald |
author_facet | Pahljina, Christian Sarny, Stephanie Hoeflechner, Lukas Falb, Thomas Schliessleder, Gernot Lindner, Marlene Ivastinovic, Domagoj Mansouri, Kaweh Lindner, Ewald |
author_sort | Pahljina, Christian |
collection | PubMed |
description | Glaucoma has a significant impact on quality of life. Here, we aimed to evaluate the influence of a reduction in glaucoma medications on quality of life and patient satisfaction after phacoemulsification combined with the Xen gel stent. We carried out a cross-sectional survey of patients who underwent phacoemulsification with the Xen gel stent at the Medical University of Graz, Austria. Quality of life was assessed using the German version of the Glaucoma Symptoms Scale (GSS)—questionnaire. Patients were also asked whether the operation reduced glaucoma medications and to indicate their overall satisfaction from 1 (totally discontented) up to 10 (totally contented). Questionnaires of 80 patients were evaluated. A total of 36 patients (45.0%) reported a reduction in glaucoma medications. Three items of the GSS were significantly better in patients who needed fewer glaucoma medications after the operation (“hard to see in daylight”, 75.0 ± 31.1 vs. 57.7 ± 39.1, p = 0.035; “hard to see in dark places”, 81.1 ± 28.7 vs. 54.9 ± 41.2, p = 0.002; and “halos around lights”, 88.3 ± 25.9 vs. 68.8 ± 38.6, p = 0.002). Patient satisfaction was significantly higher when the procedure led to a reduction in glaucoma medication (8.3 ± 2.0 vs. 6.8 ± 3.1; p = 0.034). The reported quality of life and patient satisfaction were significantly better when phacoemulsification with the Xen gel stent reduced the number of glaucoma medications needed. |
format | Online Article Text |
id | pubmed-9225126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92251262022-06-24 Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent Pahljina, Christian Sarny, Stephanie Hoeflechner, Lukas Falb, Thomas Schliessleder, Gernot Lindner, Marlene Ivastinovic, Domagoj Mansouri, Kaweh Lindner, Ewald J Clin Med Article Glaucoma has a significant impact on quality of life. Here, we aimed to evaluate the influence of a reduction in glaucoma medications on quality of life and patient satisfaction after phacoemulsification combined with the Xen gel stent. We carried out a cross-sectional survey of patients who underwent phacoemulsification with the Xen gel stent at the Medical University of Graz, Austria. Quality of life was assessed using the German version of the Glaucoma Symptoms Scale (GSS)—questionnaire. Patients were also asked whether the operation reduced glaucoma medications and to indicate their overall satisfaction from 1 (totally discontented) up to 10 (totally contented). Questionnaires of 80 patients were evaluated. A total of 36 patients (45.0%) reported a reduction in glaucoma medications. Three items of the GSS were significantly better in patients who needed fewer glaucoma medications after the operation (“hard to see in daylight”, 75.0 ± 31.1 vs. 57.7 ± 39.1, p = 0.035; “hard to see in dark places”, 81.1 ± 28.7 vs. 54.9 ± 41.2, p = 0.002; and “halos around lights”, 88.3 ± 25.9 vs. 68.8 ± 38.6, p = 0.002). Patient satisfaction was significantly higher when the procedure led to a reduction in glaucoma medication (8.3 ± 2.0 vs. 6.8 ± 3.1; p = 0.034). The reported quality of life and patient satisfaction were significantly better when phacoemulsification with the Xen gel stent reduced the number of glaucoma medications needed. MDPI 2022-06-15 /pmc/articles/PMC9225126/ /pubmed/35743517 http://dx.doi.org/10.3390/jcm11123450 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pahljina, Christian Sarny, Stephanie Hoeflechner, Lukas Falb, Thomas Schliessleder, Gernot Lindner, Marlene Ivastinovic, Domagoj Mansouri, Kaweh Lindner, Ewald Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent |
title | Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent |
title_full | Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent |
title_fullStr | Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent |
title_full_unstemmed | Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent |
title_short | Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent |
title_sort | glaucoma medication and quality of life after phacoemulsification combined with a xen gel stent |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225126/ https://www.ncbi.nlm.nih.gov/pubmed/35743517 http://dx.doi.org/10.3390/jcm11123450 |
work_keys_str_mv | AT pahljinachristian glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent AT sarnystephanie glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent AT hoeflechnerlukas glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent AT falbthomas glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent AT schliessledergernot glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent AT lindnermarlene glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent AT ivastinovicdomagoj glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent AT mansourikaweh glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent AT lindnerewald glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent |